Esperion Therapeutics, Inc.
Develops oral ACLY inhibitors to lower high LDL-C and cardiovascular risk.
ESPR | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 3891 RANCHERO DRIVE, SUITE 150, 48108 ANN ARBOR
- Website:
- https://www.esperion.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Esperion Therapeutics, Inc. is a commercial-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk. The company's core products are based on a novel mechanism of action, being the first to bring an ATP Citrate Lyase (ACLY) inhibitor to market. These treatments are approved in the U.S. and Europe, addressing significant unmet needs in cardiovascular disease management, particularly for patients with statin intolerance. Esperion utilizes commercial partnerships to enable global access to its medicines while advancing a pipeline focused on next-generation inhibitors for life-threatening diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Esperion Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Esperion Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Esperion Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
